HK1199025A1 - Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors mogat-2 - Google Patents

Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors mogat-2

Info

Publication number
HK1199025A1
HK1199025A1 HK14112466.4A HK14112466A HK1199025A1 HK 1199025 A1 HK1199025 A1 HK 1199025A1 HK 14112466 A HK14112466 A HK 14112466A HK 1199025 A1 HK1199025 A1 HK 1199025A1
Authority
HK
Hong Kong
Prior art keywords
mogat
inhibitors
derivatives useful
sulfonamide derivatives
benzyl sulfonamide
Prior art date
Application number
HK14112466.4A
Other languages
English (en)
Chinese (zh)
Inventor
Maria Carmen Fernandez
Maria Rosario Gonzalez-Garcia
Lance Allen Pfeifer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199025(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of HK1199025A1 publication Critical patent/HK1199025A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK14112466.4A 2012-01-31 2014-12-11 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors mogat-2 HK1199025A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06
PCT/US2013/022870 WO2013116075A1 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors

Publications (1)

Publication Number Publication Date
HK1199025A1 true HK1199025A1 (en) 2015-06-19

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112466.4A HK1199025A1 (en) 2012-01-31 2014-12-11 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors mogat-2

Country Status (27)

Country Link
US (1) US8575352B2 (xx)
EP (1) EP2809651B1 (xx)
JP (1) JP2015511232A (xx)
KR (1) KR20140106750A (xx)
CN (1) CN104066719B (xx)
AP (1) AP2014007794A0 (xx)
AR (1) AR089771A1 (xx)
AU (1) AU2013215468A1 (xx)
BR (1) BR112014018636A8 (xx)
CA (1) CA2859995A1 (xx)
CL (1) CL2014001861A1 (xx)
CO (1) CO7010839A2 (xx)
CR (1) CR20140322A (xx)
DO (1) DOP2014000178A (xx)
EA (1) EA201491276A1 (xx)
ES (1) ES2590929T3 (xx)
GT (1) GT201400167A (xx)
HK (1) HK1199025A1 (xx)
IL (1) IL233712A0 (xx)
MA (1) MA35886B1 (xx)
MX (1) MX2014008599A (xx)
PE (1) PE20141679A1 (xx)
PH (1) PH12014501711A1 (xx)
SG (1) SG11201404106QA (xx)
TW (1) TW201343629A (xx)
WO (1) WO2013116075A1 (xx)
ZA (1) ZA201404836B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
ES2571577T3 (es) 2012-01-31 2016-05-26 Lilly Co Eli Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2
AU2013341584A1 (en) 2012-11-06 2015-04-30 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as MoGAT-2 inhibitors
US10934244B2 (en) 2015-06-15 2021-03-02 Nmd Pharma A/S Compounds for use in treating neuromuscular disorders
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
KR20210114001A (ko) 2019-01-11 2021-09-17 시오노기 앤드 컴파니, 리미티드 Mgat2 저해 활성을 갖는 다이하이드로피라졸로피라지논 유도체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
AU2005303492A1 (en) * 2004-11-10 2006-05-18 Pfizer Inc. Substituted N-sulfonylaminobenzyl-2-phenoxy acetamide compounds
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物
AU2007297285A1 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
EP2078719A4 (en) 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
CA2669311C (en) * 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2751244A1 (en) 2009-02-23 2010-08-26 Msd K.K. Pyrimidin-4(3h)-one derivatives
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
ES2571577T3 (es) 2012-01-31 2016-05-26 Lilly Co Eli Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2

Also Published As

Publication number Publication date
DOP2014000178A (es) 2014-08-31
AR089771A1 (es) 2014-09-17
AU2013215468A1 (en) 2014-07-10
EA201491276A1 (ru) 2014-10-30
CL2014001861A1 (es) 2014-11-07
GT201400167A (es) 2015-05-28
BR112014018636A8 (pt) 2017-07-11
US8575352B2 (en) 2013-11-05
AP2014007794A0 (en) 2014-07-31
BR112014018636A2 (xx) 2017-06-20
CN104066719B (zh) 2016-08-24
MX2014008599A (es) 2014-08-22
CO7010839A2 (es) 2014-07-31
EP2809651B1 (en) 2016-06-29
SG11201404106QA (en) 2014-08-28
ES2590929T3 (es) 2016-11-24
MA35886B1 (fr) 2014-12-01
CR20140322A (es) 2014-08-25
CN104066719A (zh) 2014-09-24
US20130197039A1 (en) 2013-08-01
ZA201404836B (en) 2017-08-30
KR20140106750A (ko) 2014-09-03
EP2809651A1 (en) 2014-12-10
WO2013116075A1 (en) 2013-08-08
PH12014501711A1 (en) 2014-10-13
TW201343629A (zh) 2013-11-01
JP2015511232A (ja) 2015-04-16
PE20141679A1 (es) 2014-11-08
CA2859995A1 (en) 2013-08-08
IL233712A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
HK1205740A1 (en) Pyrrolotriazinone derivatives
HK1199025A1 (en) Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors mogat-2
HK1205508A1 (en) New bicyclicpyridine derivatives
EP2870140B8 (en) Tetrahydroquinazolinone derivatives as parp inhibitors
SG11201503447QA (en) Oxazolidin-2-one-pyrimidine derivatives
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
RS56703B1 (sr) Novi derivati fenil-tetrahidroizokinolina
HK1199024A1 (zh) 可作為 抑制物使用之新型嗎啉基衍生物
ZA201502878B (en) Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors